$4.96
Value $190M
TRDA and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$4.96
Value $190M
$389.68
Value $354B
Entrada Therapeutics (TRDA) has a market value of $190M and UnitedHealth (UNH) $354B. Over the last year, with dividends, TRDA moved -43.3% and UNH +24.3%. Dividend yield: TRDA none, UNH 2.32%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
TRDA$190M
UNH$354B
UNH is 1,863 times TRDA
Revenue, 12 months
TRDA$4.0M
UNH$450B
UNH is 113,066 times TRDA
Net income, 12 months
TRDA-$161M
UNH$15.9B
Operating margin
TRDA-4,303.8%
UNH5.3%
4,309.1 points apart
ROIC
TRDA-50.1%
UNH11.3%
61.4 points apart
P/E
TRDA–
UNH22.3
Dividend yield
TRDA0.0%
UNH2.3%
2.3 points apart
5-year return
TRDA-85.5%
UNH-5.1%
80.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
TRDA-85.5%
UNH-5.1%
| Period | TRDAWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -43.3%Price -43.3% | +24.3%Price +21.1% |
| 3 years since November 17, 2023 | -69.4%-32.6% a yearPrice -69.4% | -22.6%-8.2% a yearPrice -27.3% |
| 5 years since November 16, 2021 | -85.5%-32.0% a yearPrice -85.5% | -5.1%-1.0% a yearPrice -13.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
TRDAEntrada TherapeuticsUNHUnitedHealth
| Price | $4.96 | $389.68 |
|---|---|---|
| Market value | $190M | $354B |
| Enterprise value (EV) | – | $399B |
| P/E | – | 22.3 |
| P/E, 5-year median | – | 25.0 |
| P/B | 1.0 | 3.4 |
| EV/EBIT | – | 16.7 |
| Free cash flow yield | – | 6.5% |
| Revenue, 12 months | $4.0M | $450B |
|---|---|---|
| Net income, 12 months | -$161M | $15.9B |
| Free cash flow, 12 months | -$136M | $22.8B |
| Earnings per share, 12 months | -$3.84 | $17.52 |
| Revenue growth, year on year | -87.9% | 11.8% |
| Revenue growth a year, past | -55.6%over 2 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | – | 88.3% |
|---|---|---|
| Operating margin | -4,303.8% | 5.3% |
| Net margin | -4,058.0% | 3.5% |
| ROIC | -50.1% | 11.3% |
| ROE | -59.8% | 15.5% |
| Cash | $193M | $28.5B |
|---|---|---|
| Total debt | $47M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.6% |
| Shareholder yield | – | 3.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($354B) is about 1,862.7 times Entrada Therapeutics ($190M), at today's prices.
Since November 16, 2021, TRDA's price moved -85.5% and UNH's -13.3%. With dividends: TRDA -85.5% (-32.0% a year), UNH -5.1% (-1.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Entrada Therapeutics and 2.32% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was -4,058.0% for Entrada Therapeutics and 3.5% for UnitedHealth, and the operating margin -4,303.8% and 5.3%. Revenue was $4.0M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.